All In Biotech

Drug Trial Radar · NCT07357103

Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)

Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives) [A Branch of the Initial Treatment Domain of the SPIRIT-PCP Platform]

Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 416 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

416

Planned (sponsor's estimate)

Start

Mar 2026

Primary completion

Mar 2029

Study completion Sep 2029

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jan 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The usual first treatment for Pneumocystis jirovecii pneumonia (PCP) is an antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX). However, some patients cannot take this medication because of allergies, side effects, or lack of response. This study asks the question: When TMP-SMX cannot be used, which alternative treatment for PCP provides the best balance of effectiveness and safety?

Conditions

  • Pneumocystis
  • Pneumocystis Infection
  • Pneumocystis Carinii Infection
  • Pneumocystis Carinii; Infection, Resulting From HIV Disease
  • Pneumocystis Jirovecii Pneumonia
  • Pneumocystis Jirovecii Infection
  • Pneumocystosis Associated With AIDS
  • Pneumocystosis; Pneumonia (Etiology)

Interventions

  • Clindamycin + primaquineDrug

    Participants randomized to this intervention will receive clindamycin in combination with primaquine as second-line therapy for the treatment of PCP. This regimen may be used for participants with Severe PCP or mild to moderate PCP in acccordance with protocol-defined disease severity and standard clinical practice.

  • PentamidineDrug

    Participants randomized to this intervention will receive pentamidine, administered intravenously, as second-line therapy for the treatment of PCP in patients with severe disease who are unable to tolerate or have contraindications to trimethoprim-sulfamethoxazole (TMP/SMX)

  • AtovaquoneDrug

    Participants randomized to. this intervention will receive atovaquone, administered orally, as second-line therapy for the treatment of PCP in participants with mild to moderate disease who are unable to tolerate or have contraindications to trimethoprim-sulfamethozaxole (TMP/SMX).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hierarchical composite outcomeTime frame: Day 30

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.